In their analysis, polygenic risk for psoriasis was associated with an increased odds of skin irAEs (P = 0.002; OR 1.79; 95% CI 1.24-2.40), while high polygenic risks for vitiligo (P = 0.0016; HR 0.58; 95% CI 0.41-0.81) and psoriasis (P = 5.5 × 10−5; HR 0.50; 95% CI 0.36-0.70), as well as low for atopic dermatitis (P = 0.0008; HR 0.57; 95% CI 0.41-0.79) were associated with longer OS under anti-PD-L1 atezolizumab monotherapy in comparison with chemotherapy (9). The gene discussed is CD274; the disease is vitiligo.